Skip to main content
Publications
Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg CN, Brown JR, Dave V, Downey C, Shillington AC, Katzenstein HM, Kirker M, Hanson S, Liu FX, Morris V, Bhanegaonkar A, Sonpavde GP. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the Real-world US PATRIOT-II Study. Clin Genitourin Cancer. 2024 Dec;22(6):102238. doi: 10.1016/j.clgc.2024.102238
Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R, Martinez D, Garcia de Albeniz Martinez X. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002
Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez-Salas N, Martin-Richard M, Alonso-Orduna V, Vera R, Gallegeo J, Capdevila J, Salud A, Nogue M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X. Effect of aflibercept plus modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma: the GEMCAD 1402 randomized clinical trial. JAMA Oncol. 2019 Aug 29;5(11):1566-73. doi: 10.1001/jamaoncol.2019.2294
Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA, Copeland G, Meyer RE, Brown AL, Chambers TM, Sok P, Danysh HE, Carozza SE, Sisoudiya SD, Hilsenbeck SG, Janitz AE, Oster ME, Scheuerle AE, Schiffman JD, Luo C, Mian A, Mueller BA, Huff CD, Rasmussen SA, Scheurer ME, Plon SE. Association between birth defects and cancer risk among children and adolescents in a population-based assessment of 10 million live births. JAMA Oncol. 2019 Jun 20. doi: 10.1001/jamaoncol.2019.1215